For instance, radiolabeled peptides and small molecules have convincingly demonstrated the ability to target the somatostatin receptor subtype-2 (SSTR2) (100) and prostate-specific membrane antigen (PSMA) (101), which are hallmarks of neuroendocrine tumors and prostate cancer, respectively. Here, SSTR2 is linked to neuroendocrine neoplasm.